EBS Emergent BioSolutions Inc.

Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors

Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors

GAITHERSBURG, Md., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as WomenInc. magazine's 2019 Most Influential Corporate Directors. 

“Sue and Kathy are trailblazers in their fields and continue to positively impact public health through their service on Emergent’s Board and their personal endeavors,” said Fuad El-Hibri, executive chairman of the board of directors of Emergent BioSolutions. “The strength of our board lies in the exemplar backgrounds and diverse perspectives each of our members bring and we are fortunate to have Sue and Kathy as engaged and passionate contributors.”

“On behalf of the Emergent family, I would like to express our sincere congratulations to Sue and Kathy for this well-deserved and prestigious recognition,” said Robert G. Kramer Sr., president and CEO of Emergent BioSolutions. “Their expert guidance, leadership, thoughtful stewardship, and personal mission to make the world a safer and healthier place help propel the company towards achieving our mission – to protect and enhance life. We are so proud of this accolade to add to their many achievements.” 

Dr. Bailey has served as a director since June 2007. She is an independent director and a member of the Compensation Committee, Nominating and Corporate Governance Committee, and Scientific Review Committee. Dr. Bailey served as a news analyst for NBC Universal, a media and entertainment company, from November 2001 to August 2006. Previously, Dr. Bailey served as Administrator, National Highway Traffic Safety Administration, as Assistant Secretary of Defense (Health Affairs) and as Deputy Assistant Secretary of Defense (Clinical Services). Dr. Bailey is a former faculty member at Georgetown Medical School and U.S. Navy officer, having achieved the rank of Lt. Commander, U.S. Navy Reserve.

Dr. Zoon has served as a director since October 2016. She is an independent director and a member of the Nominating and Corporate Governance Committee, Scientific Review Committee, and Strategic Operations Committee. Dr. Zoon is currently a Scientist Emeritus with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Previously at NIAID/NIH she was the Chief of the Cytokine Biology Section, Director of the Division of Intramural Research, and Deputy Director for Planning and Development at the DIR. Dr. Zoon has also served as the Principal Deputy Director of the Center for Cancer Research at the National Cancer Institute, and as the Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. She has been a member of the National Academy of Medicine since 2002.

WomenInc. magazine is a cultural catalyst for professional women—a media platform that showcases and drives positive dialogue on and about women. This issue also features a discussion with Katy Strei, Emergent’s executive vice president, human resources and corporate communications and chief human resources officer, on “Shaping a Diverse and Inclusive Culture” and how Emergent has opened the aperture in thinking creatively and broadly about diversity and inclusion.

The full WomenInc. Influential Corporate Directors listing is available online and the WomenInc.'s winter issue is available nationwide at Barnes & Noble and newsstands.

About Emergent BioSolutions

Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats. We aspire to be a Fortune 500 company recognized for protecting and enhancing life, driving innovation, and living our values. Additional information about the company may be found at Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

Media Contact:

Lynn Kieffer

Vice President, Corporate Communications

240-631-3391

EN
20/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manu...

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax. “We are pleased with the U.S. FDA approval of our sBLA f...

 PRESS RELEASE

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approv...

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved nasal naloxone spray for emergency treatment of opioid overdose. This historic approval made the life-saving medication easy to administer in both medical and community settings, ultimately l...

 PRESS RELEASE

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan fr...

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and its shareholders. “For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent’s mission to protect and save lives,” said Joe Papa, president and CEO of Emergent. “On behalf of the Board and the entire Emergent team, I want to...

 PRESS RELEASE

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Emergent BioSolutions Reports Third Quarter 2025 Financial Results Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior yearThird Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%Raising the Full Year 2025 Revenue and Profitability GuidanceStrong Sequential Naloxone Revenue Growth, Primarily Driven b...

 PRESS RELEASE

Emergent BioSolutions Releases New Survey Findings Revealing Heightene...

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch